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Rheumatoid arthritis (RA) is a systemic autoimmune disease that is characterized by chronic 
inflammation of joints, leading to synovial hyperplasia, infiltration of leukocytes and 
progressive destruction of cartilage and bone. Proinflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα), interleukin (IL)-1 and IL-6, contribute to the development of 
RA by induction of various inflammatory mediators and recruitment, differentiation and 
proliferation of inflammatory cells. However, the role of proinflammatory cytokines in joint 
tissues during development of RA is poorly understood. To elucidate this, I focused on how 
the expression and function of the proinflammatory cytokines in joint tissues are regulated in 
mouse collagen-induced arthritis (CIA). 
 Collagen-induced arthritis is known to be accelerated by lipopolysaccharide (LPS), a 
major component of the outer membrane of gram-negative bacteria. LPS-accelerated CIA 
(LPS-CIA) may have characteristics of some pathogenetic mechanisms similar with RA 
because systemic infections cause acute exacerbations of RA. To uncover the pathogenetic 
mechanisms of LPS-CIA, I analyzed the sequence and timing of the production of 
inflammatory mediators and anti-type II collagen (CII) antibodies. LPS-CIA is accompanied 
by acute onset and histopathological changes that are characterized in RA. LPS-CIA mice 
showed marked increases in expression levels of mRNA of inflammatory mediators, such as 
TNFα, in their arthritic paws and of serum anti-CII antibody concentration after LPS injection. 
Moreover, anti-TNFα neutralizing antibodies inhibited the development of LPS-CIA and a 
single injection of recombinant mouse TNFα induced increases in anti-CII antibody 
concentrations, suggesting TNFα may contribute to the development of arthritis by both 
initiation of inflammation and production of autoantibodies. These data suggest that 
exacerbation of CIA by LPS is associated with rapid production of proinflammatory cytokines 
and anti-CII antibodies.  
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 Most proinflammatory cytokines associated with RA are regulated by the nuclear 
factor-κB (NF-κB). NF-κB is activated by a variety of inflammatory stimuli, such as TNFα 
and LPS, mediated by IκB kinase beta (IKKβ). To elucidate the role of NF-κB in regulation 
and function of proinflammatory cytokines in joint tissues, I investigated the mechanisms of 
the anti-arthritic effect of a novel IKKβ inhibitor Compound D. Compound D selectively 
inhibited IKKβ kinase activity and blocked the NF-κB signaling pathway. In addition, 
Compound D inhibited NF-κB-driven production of proinflammatory cytokines in vitro and 
in vivo. Furthermore, Compound D distributed to the arthritic paws compared to healthy paws, 
where it downregulated proinflammatory cytokines. Moreover, Compound D completely 
inhibited arthritis progression even when treatment occurred after disease onset. These data 
suggest that NF-κB-dependent proinflammatory cytokines in local joint tissues play an 
important role in the development of CIA. 
 In conclusion, I demonstrated that the NF-κB-dependent production of 
proinflammatory cytokines in local joint tissues amplify inflammation and develop arthritis. 
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Abbreviations 
 
AP-1, activator protein-1 
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CRE, cAMP response element 
CIA, collagen-induced arthritis 
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EDTA, ethylenediaminetetraacetic acid 
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IC50, 50% inhibitory concentration 
IκB, inhibitor of nuclear factor-κB 
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IL, interleukin 
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LPS, lipopolysaccharide 
LPS-CIA, lipopolysaccharide-accelerated collagen-induced arthritis 
MIP-2, macrophage inflammatory protein-2 
MMP, matrix metalloproteinase 
ND, not detected 
NS, not significant 
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NFAT, nuclear factor of activated T cells 
NF-κB, nuclear factor-κB 
PBS, phosphate buffered saline 
PCR, polymerase chain reaction 
RA, rheumatoid arthritis 
RANKL, receptor activator of nuclear factor-κB ligand 
SD, standard deviation 
SE, standard error 
SRE, serum response element 
TLR, Toll-like receptor 
TNFα, tumor necrosis factor alpha 
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Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that affects 
approximately 1% of the population worldwide. The disease is primarily manifested as joint 
inflammation characterized by synovitis. Histopathological features in the joints are synovial 
hyperplasia, infiltration of leukocytes and progressive destruction of cartilage and bone 
(Firestein, 2003). The joint inflammation results in pain, swelling and stiffness, which lead to 
loss of function of the joints. 
 Development of RA is thought to occur in a complex process associated with 
autoimmunity and inflammation. RA is understood to be an autoimmune disease initiated by 
autoantibodies. Rheumatoid factor is the classic autoantibody in RA (Scott et al., 2010). The 
autoantibodies activate complement systems by formation of immune complexes in 
combination with self-antigens and induce recruitment of inflammatory cells into the 
synovium (Firestein, 2003; Nandakumar and Holmdahl, 2006). Synovitis in RA patients is 
characterized by an infiltrate of inflammatory cells, including macrophages and CD4
+
 T cells. 
Macrophages are activated partly by immune complexes binding to Fcγ receptors and 
complement receptors on their surface. In addition, macrophages present arthritogenic antigen 
to CD4
+
 T cells owing to contacts between T cell receptors and major histocompatibility 
complex molecules, leading to enhanced T cell reactivity. B cells are activated by stimulation 
from T cells followed by further production of autoantibodies leading to immune complex 
formation (Firestein, 2003). In the inflammatory joint tissues, the immune complexes and 
invasive inflammatory cells induce proliferation of synovial cells, which results in synovial 
hyperplasia and subsequent pannus formation. Synovial cells in the region secrete various 
mediators, which contribute to cartilage matrix degradation and bone erosion (McInnes and 
Schett, 2011; Redlich and Smolen, 2012). 
 Inflammatory mediators, such as cytokines, chemokines and proteases, play an 
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important role in inducing inflammation and tissue destruction (Godessart and Kunkel, 2001; 
Goldring, 2002; Firestein, 2003; Brown et al., 2008; Goldring and Marcu, 2009). These 
inflammatory mediators are detectable in high concentrations in synovial fluid or serum of 
RA patients (Eastgate et al., 1988; Houssiau et al., 1988; Tetta et al., 1990; Troughton et al., 
1996; Yoshihara et al., 2000; Ziolkowska et al., 2000; Kraan et al., 2001; Tchetverikov et al., 
2004). In particular, proinflammatory cytokines including tumor necrosis factor alpha (TNFα), 
interleukin (IL)-1β, IL-6 and IL-17 contribute to the development of RA (Firestein, 2003; 
Brown et al., 2008). These cytokines induce recruitment, differentiation, and proliferation of 
inflammatory cells and amplify inflammation by further production of various inflammatory 
mediators (Choy and Panayi, 2001; Firestein, 2003; Brown et al., 2008). Therefore, 
proinflammatory cytokines are believed to be promising targets for RA therapeutics. 
Supporting this idea, some biologics targeting proinflammatory cytokines have improved the 
effectiveness of RA therapy (Taylor and Feldmann, 2009). Thus, the proinflammatory 
cytokines may be a key factor in the development of arthritis. 
 As described above, various factors, such as proinflammatory cytokines, are involved 
in the development of arthritis. Based on the pathology, several therapeutics targeting immune 
response and inflammatory processes were developed and expanded treatment options; 
however, some patients with RA remain unresponsive to the therapy. Furthermore, some 
patients have acute onset and exacerbations of the disease. So far, the pathogenic mechanisms 
underlying these cases are poorly understood. Thus, RA pathology is complex and has not yet 
been fully elucidated. In particular, the regulation of the expression and function of the 
proinflammatory cytokines in the joint tissues, which are the primary target tissue of RA, is 
not clarified. 
 In my present study, in order to elucidate the role of proinflammatory cytokines in 
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joint tissues during development of arthritis, I analyzed the mechanism of lipopolysaccharide 
(LPS)-induced exacerbation of arthritis and the role of nuclear factor-κB (NF-κB) in 
regulation of expression of proinflammatory cytokines in joint tissues using the mouse 
collagen-induced arthritis (CIA) model. 
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Introduction 
 
It is well known that some patients with RA have acute onset and exacerbations of their 
disease. Microbial infections are thought to be one of the triggers for onset and exacerbation 
of autoimmune diseases, including RA (Carty et al., 2003; Leirisalo-Repo, 2005; Getts and 
Miller, 2010). A number of studies suggest a possible role for LPS, a major component of the 
outer membrane of gram-negative bacteria, in RA. The serum and synovial fluids of RA 
patients contain higher concentrations of antibodies against Escherichia coli (E. coli) or 
LPS-binding protein than do those of healthy subjects (Heumann et al., 1995; Aoki et al., 
1996). 
 CIA is a common animal model with similarities to RA in both cause and pathology. 
After immunization of DBA/1J mice with type II collagen (CII) in complete Freund's 
adjuvant, synovial hyperplasia, infiltration of inflammatory cells and destruction of cartilage 
and bone occur in the joint tissue of both CIA mice and humans with RA (Williams, 2007). In 
addition, an autoantibody, namely an anti-CII antibody, triggers CIA (Cho et al., 2007). 
Injection of a cocktail with monoclonal anti-CII antibodies induces arthritis in mice 
(Holmdahl et al., 1990; Terato et al., 1992). Furthermore, proinflammatory cytokines play 
important roles in the pathogenetic process of CIA. Antibodies against TNFα, IL-1β and IL-6 
are effective against CIA (Williams et al., 1992; Takagi et al., 1998; Williams et al., 2000). It 
is well known that CIA is accelerated by LPS (Caccese et al., 1992; Terato et al., 1995; Terato 
et al., 1996; Takahashi et al., 1999). Caccese et al. have demonstrated that LPS induces acute 
onset of inflammation after LPS injection in CII-immunized mice, in contrast with 
unmodified CIA, which develops slowly (Caccese et al., 1992). Moreover, an administration 
of LPS reactivates paw inflammation in CIA mice (Yoshino et al., 1999; Yoshino and Ohsawa, 
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2000). LPS-accelerated CIA (LPS-CIA) is more useful than CIA alone for screening of 
antirheumatic drugs because it enables not only shortening the duration of experiments but 
also more accurate evaluation of incidence and severity (Caccese et al., 1992). On the other 
hand, these findings suggest that LPS plays a role in the exacerbation of RA and the 
characteristics of some pathogenetic mechanisms are similar in LPS-CIA and RA. Therefore, 
LPS-CIA is a valuable disease model for investigating the acute phase of RA. However, few 
studies have analyzed the pathogenetic mechanisms of LPS-CIA. In particular, there are no 
detailed analyses focusing on the period before the onset of arthritis. 
 The purpose of this chapter is to uncover the mechanism of LPS-induced 
exacerbation of arthritis. In order to achieve the purpose, I analyzed the pathology from the 
perspective of the sequence and timing of the production of inflammatory mediators and 
anti-CII antibodies and related this to histopathological findings. 
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Materials and Methods 
 
Animals 
Female DBA/1JNCrj mice were purchased from Charles River (Tokyo, Japan). All mice were 
used at the age of 7-10 weeks. All experimental procedures were performed in accordance 
with the in-house guidelines of the Institutional Animal Care and Use Committee of Daiichi 
Sankyo Co., Ltd. 
 
Induction and assessment of arthritis in mice 
The mice were immunized by intradermal injections at the base of the tail with an emulsion 
containing 150 μg of bovine CII (Collagen Gijutsu-Kenshukai, Tokyo, Japan) in Freund's 
complete adjuvant containing Mycobacterium butyricum (Difco Laboratories, Detroit, USA). 
After 17-21 days, the mice were injected subcutaneously with 0.2 mg/kg of LPS of E. coli 
O111:B4 (Difco Laboratories) or intravenously with 2, 20 and 200 ng/kg of recombinant 
mouse TNFα (Genzyme, Boston, USA) in place of LPS. Anti-TNFα neutralizing antibodies 
and control IgG were purified from the ascites of mice injected with hybridoma (MP6-XT22 
and Y13-259, respectively). The antibodies (25 mg/kg) were intraperitoneally administered 
once daily from the day before to 6 days after LPS injection. The severity of arthritis of each 
paw was scored periodically on a scale of 0-3 according to the following criteria: 0, normal; 
0.5, swelling of one digit; 1, swelling of more than two digits or redness of paw; 2, swelling 
of part of paw; and 3, swelling of entire paw. 
 
Histopathology 
The hind paws of the mice were severed between the knee and ankle, fixed in phosphate 
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buffered saline (PBS) containing 10% (v/v) formaldehyde, decalcified in 10% (w/v) 
ethylenediamine tetraacetic acid (EDTA) and embedded in paraffin. The paws were sliced 
horizontally to the footpad, sectioned, and stained with hematoxylin and eosin. Synovium and 
bone/cartilage tissues of their tarsal joints were evaluated by light microscopy. Infiltration of 
leukocytes, proliferation of synovial cells and osteoclast formation were scored on a scale of 
0-3 depending on the number of cells in the synovium, ranging from normal to spreading in 
most areas. Edema was scored on a scale of 0-3 depending on accumulation of excess liquid 
in the synovium or articular cavities, ranging from normal to appearance in most areas. 
Destruction of bone and cartilage tissues was scored on a scale of 0-3 ranging from no 
damage to complete loss of the articular cartilage or bone structure. The scoring was 
performed according to the following criteria: 0, no abnormality detected; 0.5, very slight; 1, 
mild; 2, moderate; and 3, severe or marked. 
 
Quantitative real-time polymerase chain reaction 
Total RNA was extracted from the hind paws of the mice that had been homogenized in 
ISOGEN (Nippon Gene, Tokyo, Japan) using Polytron and reverse transcribed to cDNA using 
SuperScript III First-Strand Synthesis Super Mix (Life Technologies, Carlsbad, USA). A 
polymerase chain reaction (PCR) was performed using a 7500 real-time PCR system (Life 
Technologies) with TaqMan Gene Expression Assays (Life Technologies) and Premix Ex-Taq 
(Takara Bio, Otsu, Japan) according to the manufacturers' instructions. The mRNA expression 
levels were normalized with those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
 
Measurement of anti-CII antibody concentration  
The concentrations of anti-CII IgG in mouse serum were measured using ELISA. Briefly, a 
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96-well plate coated with 0.1 μg/well of bovine CII was incubated overnight at 4°C, then 
washed with PBS containing 0.05% (v/v) Tween 20 followed by blocking with PBS 
containing 1% (w/v) bovine serum albumin (BSA), 5% (w/v) sucrose, and 0.05% (w/v) 
sodium azide for 1 h at room temperature. After washing, the plates were incubated with the 
serum for 2 h at room temperature. The plates were then washed and incubated with goat 
anti-mouse IgG conjugated with horseradish peroxidase for 2 h at room temperature. After 
washing, the plates were incubated with tetramethyl benzidine substrate for 20 min and the 
optical density of the wells at 450 nm was measured. The concentrations of anti-CII IgG were 
quantitated using a standard curve derived from anti-human CII IgG (Daiichi Fine Chemical, 
Takaoka, Japan). 
 
Statistical analysis 
The data are expressed as mean ± standard error (SE). Statistical significance was determined 
by a parametric Dunnett's test or Student's t-test for expression level of mRNA and anti-CII 
IgG concentrations, by a nonparametric Dunnett's test for histopathological scores and by a 
Wilcoxon's rank sum test for arthritis scores. To elucidate the correlation between the 
expression level of mRNA and the arthritis score, a Spearman's rank order correlation test was 
used. 
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Results 
 
LPS induces arthritis in CII-immunized mice 
CII-immunized DBA/1JNCrj mice were subcutaneously injected with LPS. Paw swelling was 
observed from Day 2; it reached a peak on Day 7, and then declined slowly until Day 17 
(Figure 1A; page 75, 76). The prevalence of swelling remained stable and high until Day 17 
(Figure 1B; page 75, 76). In contrast, the CII-immunized mice injected with saline did not 
show significant arthritis in terms of both severity and prevalence until Day 17 (Figure 1A, 
B; page 75, 76). These findings show that LPS induces arthritis in CII-immunized mice. 
 Next, the histopathological features of synovium and bone/cartilage tissues in the 
tarsal joints of LPS-CIA mice were assessed. The inflammatory features were not observed in 
the normal mice (Figure 1D, G; page 75, 76). From the onset of the arthritis on Day 1, 
characteristic features, especially infiltration of leukocytes and edema, were observed (Figure 
1C; page 75, 76). The leukocytes were mainly neutrophils. On Day 3, a number of neutrophils 
infiltrated the synovium (Figure 1E; page 75, 76). In addition, edema reached maximal levels 
(Figure 1C, H; page 75, 76). Furthermore, proliferation of synovial cells, destruction of 
bone/cartilage and osteoclast formation appeared (Figure 1C, E, H; page 75, 76). The 
proliferating synovial cells were both macrophage-like and fibroblast-like. On Day 7, the 
proliferation of synovial cells and destruction of bone/cartilage progressed (Figure 1C, F, I; 
page 75, 76). Along with development of bone destruction, an increase in the number of 
osteoclasts around the area of destruction was observed. The infiltrated neutrophils reached 
sustained level and remained locally. On Day 19, proliferation of synovial cells and tissue 
destruction remained mild to moderate, although most histopathological features, such as 
infiltration of leukocytes and edema, resolved almost completely (Figure 1C; page 75, 76). 
17 
These findings indicate that joints of LPS-CIA mice have similar histopathological features to 
those of humans with RA. 
 
Gene expression of inflammatory mediators increases in LPS-CIA paws 
To evaluate the association of inflammatory mediators such as cytokines, chemokines and 
proteases with the development of LPS-CIA, gene expression level of TNFα, IL-1β, IL-6, 
IL-17A, receptor activator of NF-кB ligand (RANKL), macrophage inflammatory protein-2 
(MIP-2: the functional IL-8 homolog in mice), matrix metalloproteinase (MMP)-3 and 
MMP-9 in the mouse paws were measured. The expression level of TNFα increased at 6 h 
after LPS injection (Figure 2A; page 77, 78). TNFα expression returned to basal levels on 
Day 3 (after the onset of arthritis) and increased again on Day 6 in parallel with the 
development of arthritis (Figure 2A; page 77, 78). Furthermore, on Days 0, 3 and 6, the 
expression level of TNFα was positively correlated with the arthritis scores (Figure 2B; page 
77, 78). Moreover, the gene expression levels of IL-1β, IL-6, IL-17A, RANKL, MIP-2, 
MMP-3 and MMP-9 also increased and their increase correlated with the development of 
arthritis (Table 1, 2; page 69, 70). These data suggest that these inflammatory mediators are 
related to the development of arthritis in this model. 
 Next, I focused on the period before the onset of arthritis and analyzed short-term 
changes in gene expression up to 24 h after LPS injection. Because LPS directly induces the 
expression of many inflammatory mediators including TNFα, IL-1β, IL-6 and MIP-2 through 
NF-κB, gene expression of inhibitor of nuclear factor-κB alpha (IκBα), which represents the 
NF-κB target gene, was measured. The mRNA level of IκBα in the paws increased by 2 h 
after LPS injection, and then decreased to the basal level at 6 h, which was maintained until 
24 h (Figure 2C; page 77, 78). These data indicate that LPS directly activated NF-κB in the 
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paws around 2 h after LPS injection. The expression of TNFα also increased by 2 h after LPS 
injection and continued to increase, at least until 24 h (Figure 2D; page 77, 78). IL-1β and 
MIP-2 also increased by 2 h and were induced again 8 h after LPS injection (Figure 2D, E; 
page 77, 78). The expression of IL-6 also increased by 2 h and was induced again 24 h after 
LPS injection (Figure 2D; page 77, 78). In contrast, the expression of MMP-3 and MMP-9 
did not change until 8 h, and the expression level of MMP-3 increased by 24 h (Figure 2E; 
page 77, 78). These data demonstrate that inflammatory mediators, in particular TNFα, IL-1β 
and MIP-2, are upregulated rapidly and continuously after direct activation of NF-κB and 
before the onset of LPS-CIA. 
 
LPS induces rapid production of anti-CII antibodies in CII-immunized mice 
To examine whether LPS induces production of specific autoantibodies, anti-CII IgG 
concentrations in the mice serum were measured. Anti-CII IgG concentrations in 
CII-immunized mice were increased by Day 6 after LPS injection although the difference in 
the concentrations between the saline and LPS injection was not statistically significant (P = 
0.0896, Figure 3A; page 79). Furthermore, analysis of short-term changes (up to 24 h after 
LPS injection) showed that anti-CII IgG concentrations increased from 2 h after LPS injection 
(Figure 3B; page 79). These data suggest that LPS induces rapid and continuous production 
of anti-CII antibodies in CII-immunized mice.  
 
TNFα is involved in development of LPS-CIA 
Because TNFα was expressed rapidly and continuously after LPS injection, the involvement 
of TNFα in the development of LPS-CIA was examined. When TNFα was injected into 
CII-immunized mice in place of LPS, severe arthritis did not occur in contrast to LPS-injected 
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mice (Figure 4A; page 80). However, in TNFα-injected mice, serum anti-CII IgG 
concentrations increased in a dose-dependent manner (Figure 4B; page 80). These data 
indicate that TNFα can induce production of anti-CII antibodies, but is not sufficient on its 
own to induce arthritis. Finally, the contribution of TNFα to LPS-CIA development was 
investigated using anti-TNFα neutralizing antibodies. Administration of anti-TNFα antibodies 
once daily from the day before to 6 days after LPS injection significantly inhibited 
development of LPS-CIA (Figure 4C; page 80). These data indicate that TNFα contributes to 
the development of LPS-CIA and participates in the process of anti-CII antibody induction.  
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Discussion 
 
Autoimmune diseases sometimes have acute onsets and periods of exacerbation, the causes 
for which have not yet been clarified. Because a number of studies have shown that LPS may 
play a role in the exacerbation of autoimmune diseases including RA, LPS-CIA is a valuable 
disease model for investigation of the acute phase of RA (Yoshino et al., 1999; Yoshino and 
Ohsawa, 2000). In this study, I elucidated details of the pathogenesis of LPS-CIA from the 
perspective of the sequence and timing of production of inflammatory mediators and anti-CII 
antibodies and related this to histopathological findings.  
 Inflammatory mediators such as cytokines, chemokines and proteases are involved in 
the development of RA through induction of inflammation and destruction of tissues. 
Upregulation of inflammatory mediators has been observed in both RA and CIA (Eastgate et 
al., 1988; Houssiau et al., 1988; Tetta et al., 1990; Troughton et al., 1996; Thornton et al., 
1999; Yoshihara et al., 2000; Ziolkowska et al., 2000; Kraan et al., 2001; Tchetverikov et al., 
2004). Previous studies have reported increased expression of mRNA of IL-1β and MMPs in 
arthritic paws of animals with LPS-CIA (Joosten et al., 1996; Raychaudhuri et al., 2003). In 
the present study, I clearly demonstrated that LPS-CIA mice have marked increases in the 
gene expression level of inflammatory mediators, including IL-1β, MMP-3 and MMP-9 in 
their arthritic paws (Table 1; page 69). The mRNA levels in them increased in parallel with 
the development of arthritis and correlated positively with arthritis severity (Table 2; page 70). 
Importantly, TNFα, IL-1β and MIP-2 were rapidly and continuously expressed after direct 
activation of NF-κB and before the onset of arthritis. In particular, the expression level of 
TNFα was greater before the onset of arthritis than after its onset. In contrast, I did not 
observe these responses for MMP-3 and MMP-9, which are overexpressed as a result of 
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aspects of joint inflammation such as the proliferation of synovial cells and infiltration of 
inflammatory cells (Yoshihara et al., 2000). These findings suggest that upregulation of TNFα, 
IL-1β and MIP-2 is involved in the mechanisms of induction of LPS-CIA. Furthermore, it is 
well known that IL-17 is involved in human RA and arthritis in animal models (Miossec and 
Kolls, 2012). IL-17A was upregulated in parallel with the development of arthritis in the paws 
of LPS-CIA mice (Table 1; page 69); suggesting IL-17A plays important roles in the 
pathogenesis of LPS-CIA.  
 I confirmed that arthritic paws of LPS-CIA mice are characterized by similar 
histopathological features as human RA; these include bone and cartilage destruction, 
synovial change and infiltration of inflammatory cells. Moreover, expression of inflammatory 
mediators is likely to correlate with histopathological findings. There is consensus that 
synovial hyperplasia caused by a marked increase in macrophage-like and fibroblast-like 
synovial cells is a hallmark of RA (Firestein, 2003). I observed proliferation of both 
macrophage-like and fibroblast-like synovial cells in parallel with the development of 
LPS-CIA, which demonstrates that LPS-CIA has this pathological hallmark in common with 
RA. In addition, I observed the increase in synovial cells from the early stages of arthritis. The 
increase in MMP-3 observed 24 h after LPS injection might reflect the proliferation of 
synovial cells, which generally takes 1 day. Notably, infiltration of neutrophils accompanied 
by edema occurred first; this coincided with the onset of arthritis, suggesting that neutrophil 
infiltration is the main cause of the inflammation in LPS-CIA. Recent studies have 
highlighted the possible contribution of neutrophils in the early phases of RA physiopathology. 
Although it is well known that mononuclear cells such as T cells, B cells and macrophages 
infiltrate the synovium in RA, neutrophils migrate to the synovial fluid before mononuclear 
cells do (Cascao et al., 2010; Wright et al., 2010; Dominical et al., 2011). Previous studies 
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have reported accumulation or participation of neutrophils in commonly-used arthritis models 
including CIA (Thornton et al., 1999; Wipke and Allen, 2001; Tanaka et al., 2006). In 
particular, the histopathology of LPS-CIA is similar to that of anti-CII antibodies and 
LPS-induced arthritis, in which neutrophils, but not T and B cells, play crucial roles in the 
development of arthritis (Tanaka et al., 2006). Thus, neutrophil infiltration may cause the 
acute inflammation in LPS-CIA; this suggests that LPS-CIA has pathogenetic mechanisms in 
common with the early phase of RA. Upregulation of MIP-2 may play a part in recruitment of 
neutrophils to inflammatory sites. Likewise, TNFα and IL-1β may result in edema formation 
by initiating acute inflammation with enhanced vascular permeability. The increase in 
osteoclasts associated with bone and cartilage destruction is consistent with increased 
expression of RANKL (Table 1; page 69). Similarly, overexpression of MMP-3 and MMP-9 
may cause cartilage destruction.  
 The rapid and continuous increase in serum anti-CII antibody concentrations may, in 
part, contribute to the development of LPS-CIA. CII is the major constituent protein of the 
cartilage of joints and autoimmunity to CII occurs in RA patients (Nandakumar and Holmdahl, 
2006). The rapidity of increase in production of serum anti-CII antibodies induced by LPS 
may be mediated via a direct effect on B cells. LPS injection results in production of 
polyclonal antibodies via stimulation of B cells (Dziarski, 1982a; Dziarski, 1982b). Anti-CII 
antibodies have the potential to induce arthritis, as evidenced by induction of articular 
inflammation by serum transfer or collagen antibody cocktail injection (Holmdahl et al., 
1990; Terato et al., 1992). Complex formation between anti-CII antibodies and CII in cartilage 
activates the complement systems and initiates recruitment of neutrophils and macrophages, 
which are activated by Fcγ receptor ligation and secrete inflammatory mediators (Cho et al., 
2007). In the present study, I detected a second induction in gene expression of IL-1β and 
23 
MIP-2 2-8 h after LPS injection, this interval of time being just after the increase in serum 
anti-CII IgG. Additionally, a previous study has shown that LPS injection of mice without CII 
immunization does not induce arthritis (Caccese et al., 1992; Takahashi et al., 1999). Thus, 
production of anti-CII antibodies and the consequent induction of continuous expression of 
inflammatory mediators may be necessary for acute onset of LPS-CIA. Furthermore, T cells 
might be involved in LPS-CIA via modulation of pathogenic B cells, which produce anti-CII 
antibodies. 
 The expression pattern of TNFα mRNA did not decrease after LPS injection and 
before the onset of arthritis, implying its important role in the development of LPS-CIA. 
Previous studies have shown that neutralizing antibodies against TNFα and soluble TNFα 
receptor fusion protein significantly ameliorate CIA (Piguet et al., 1992; Williams et al., 1992; 
Wooley et al., 1993). Additionally, anti-TNFα antibodies are effective when treated after the 
onset of arthritis induced by a booster injection of CII and subsequent LPS injection (Joosten 
et al., 1996); however, whether the antibodies are effective when treated before the onset of 
LPS-CIA has yet to be clarified. In the present study, I have confirmed the effectiveness of 
anti-TNFα antibodies treated before the onset of LPS-CIA, validating that TNFα is an 
important molecule in the pathogenesis of LPS-CIA. A single intra-articular injection of 
TNFα accelerates the onset of arthritis in rats immunized with CII (Cooper et al., 1992). In 
addition, comparable to LPS, an intraperitoneal administration of recombinant IL-1β can 
induce arthritis in CII-immunized mice (Caccese et al., 1992). However, TNFα did not induce 
severe arthritis when it was injected intravenously, suggesting that systemic exposure of 
TNFα is insufficient to induce arthritis. Interestingly, this experiment showed TNFα has the 
potential to induce production of anti-CII antibodies. This finding suggests that TNFα 
contributes to the development of LPS-CIA through participation in the production process of 
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anti-CII antibodies. On the other hand, because TNFα alone is not sufficient to induce arthritis, 
the findings raise the possibility that involvement of other proinflammatory cytokines, such as 
IL-1β and IL-6, could be necessary for the development of LPS-CIA.  
 The development and severity of RA are linked to genetic and environmental factors. 
Microbial infections, which may be a potent source of LPS, may be one of the triggers for 
autoimmune diseases, including RA (Carty et al., 2003; Leirisalo-Repo, 2005; Getts and 
Miller, 2010). It is recognized that systemic infections cause acute exacerbations of RA. One 
of the multiple possible mechanisms by which infections may trigger autoimmunity is the 
adjuvant effects of pathogens mediated by Toll-like receptors (TLRs) and other 
pattern-recognition receptors on antigen-presenting cells; this would lead to production of 
inflammatory mediators which in turn would result in tissue damage (Getts and Miller, 2010). 
A number of studies suggest a possible role for LPS or its cellular receptor, TLR4, in RA. The 
serum and synovial fluids of RA patients contain higher concentrations of antibodies against 
E. coli or LPS-binding protein than do those of healthy subjects (Heumann et al., 1995; Aoki 
et al., 1996). In animal models, the spontaneous arthritis of IL-1 receptor antagonist knockout 
mice is markedly suppressed by crossing with TLR4-deficient mice (van den Berg et al., 
2007). Moreover, blocking of TLR4 by receptor antagonists suppresses experimental arthritis 
in mice (van den Berg et al., 2007; O'Neill et al., 2009). I confirmed that, after LPS injection, 
LPS-CIA mice had increased inflammatory mediators in their paws, similar to that associated 
with infection. Taken together with these findings, LPS-CIA may have pathogenetic 
mechanisms in common with infection-associated RA.  
 In summary, I have demonstrated that LPS induces arthritis in CII-immunized mice 
and that the onset of the arthritis is preceded by rapid and continuous production of 
inflammatory mediators and anti-CII antibodies. This finding suggests that production of 
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these humoral factors induces the development of LPS-CIA. In particular, TNFα may 
contribute to the development of LPS-CIA via both initiation of inflammation and production 
of anti-CII antibodies. It is possible that the rapid and continuous production of inflammatory 
mediators and autoantibodies is the mechanism underlying the exacerbation of arthritis. 
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“Role of NF-κB in regulation of expression of 
proinflammatory cytokines in joint tissues” 
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Introduction 
 
Most proinflammatory cytokines associated with RA are regulated by NF-κB. NF-κB plays an 
important role in immune response, inflammation, cell differentiation, proliferation and 
survival (Baeuerle and Henkel, 1994; Hayden and Ghosh, 2004; Perkins, 2007). 
Dysregulation of NF-κB is observed in various diseases, such as cancer and inflammatory 
diseases including RA (Tak and Firestein, 2001; Senftleben and Karin, 2002; Viatour et al., 
2005; Brown et al., 2008). In resting cells, NF-κB exists as an inactive form through 
association with IκB in the cytoplasm. In the canonical pathway, a variety of stimuli such as 
TNFα and LPS induces phosphorylation and subsequent polyubiquitination of IκB, leading to 
degradation through the 26S proteasome pathway. NF-κB released from IκB translocates into 
the nucleus and initiates the transcription of target genes, including TNFα, IL-1 and IL-6 
(DiDonato et al., 1996; Karin, 1999; Guha and Mackman, 2001; Makarov, 2001; Tak and 
Firestein, 2001). 
 The phosphorylation of IκB is catalyzed by the IκB kinase (IKK) complex, which 
consists of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, NF-κB essential 
modulator (Karin, 1999; Ghosh and Karin, 2002). Ample evidence indicates that IKKβ, but 
not IKKα, is required for NF-κB activation in response to inflammatory stimuli (Li et al., 
1999; Ghosh and Karin, 2002), suggesting that IKKβ is a key factor in the production of 
proinflammatory cytokines in inflammatory conditions. Therefore, further understanding of 
the mechanisms of NF-κB regulation by IKKβ is of great interest for RA therapeutics. Several 
small molecule inhibitors of IKKβ have been identified, and the efficacy of each inhibitor has 
been clearly demonstrated in arthritis models (McIntyre et al., 2003; Podolin et al., 2005; 
Schopf et al., 2006; Mbalaviele et al., 2009); however, studies using diverse chemical classes 
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of IKKβ inhibitors with characteristic mechanisms of action are still required to validate the 
role of NF-κB in the development of RA. In fact, there is no report where IKKβ inhibitors are 
analyzed from the perspective of the relationship between the tissue distribution of the 
compounds and the regulation of proinflammatory cytokines in the arthritic joints, which are 
the primary target tissues of RA. Compound D is a novel IKKβ inhibitor, which shows potent 
IKKβ inhibitory activity, favorable physical properties, good plasma exposure and efficacy in 
CIA models (Shimizu et al., 2010; Shimizu et al., 2011a; Shimizu et al., 2011b). However, the 
molecular mechanisms and joint tissue distribution of the compound have not been fully 
investigated. 
 The purpose of this chapter is to clarify the role of NF-κB in regulation and function 
of proinflammatory cytokines in joint tissues. In order to achieve the purpose, I investigated 
the mechanisms of anti-arthritic effect of Compound D because the compound exhibited 
suitable properties for studying the role of NF-κB in the local joint tissues, such as selective 
inhibition of the NF-κB signaling pathway and preferential distribution in the arthritic paws.  
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Materials and Methods 
 
Animals 
Male BALB/c mice and female DBA/1J mice were purchased from Charles River and Japan 
SLC (Shizuoka, Japan), respectively. All mice were used at the age of 7-10 weeks. All 
experimental procedures were performed in accordance with the in-house guidelines of the 
Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. 
 
Materials 
Compound D was synthesized at Daiichi Sankyo Co., Ltd. (Tokyo, Japan). LPS (E. coli 
O111:B4) and Freund’s complete adjuvant containing Mycobacterium butyricum were 
purchased from Difco Laboratories. PathDetect cis-reporter luciferase plasmids for NF-κB, 
activator protein-1 (AP-1), nuclear factor of activated T cells (NFAT), serum response element 
(SRE), cAMP response element (CRE) and interferon-stimulated response element (ISRE), 
were purchased from Agilent Technologies (Santa Clara, USA). Fugene HD, EDTA-free 
protease inhibitor cocktail, Pefablock and leupeptin were purchased from Roche Diagnostics 
(Basel, Switzerland). 
 
Kinase assay 
Kinase selectivity was assessed using a commercial kinase profiling service (Carna 
Biosciences, Kobe, Japan). Kinase activities of IKKβ and IKKα were measured by an 
IMAP
TM
 assay using ATP at the concentrations around Km for each kinase. 
 
Reporter assay 
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Reporter assay was performed as previously reported (Wen et al., 2006), with some 
modifications. In brief, 293T cells (American Type Culture Collection) grown in a 10 cm dish 
in Dulbecco's modified Eagle medium supplemented with 10% (v/v) fetal bovine serum 
(FBS), 50 units/mL of penicillin and 50 μg/mL of streptomycin were transfected with 10 μg of 
reporter luciferase plasmids using Fugene HD. The following day, the transfected cells were 
harvested and plated at a density of 2×10
4
 cells/well in a poly-D-lysine 96-well plate (BD 
Biosciences, San Jose, USA). The cells were pretreated with various concentrations of 
Compound D just before the stimulation as follows: 3 ng/mL of TNFα for NF-κB, 5 ng/mL of 
phorbol 12-myristate 13-acetate for AP-1 and SRE, 5 ng/mL of phorbol 12-myristate 
13-acetate and 1 μg/mL of ionomycin for NFAT, 5 μM forskolin for CRE, 4,000 units/mL of 
interferon beta for ISRE. After incubation for 6 h (TNFα) or 24 h (the others), the cells were 
lysed with Bright-Glo (Promega, Madison, USA) and their luciferase activities were 
measured using ARVO-MX (PerkinElmer, Waltham, USA). For evaluation of cytotoxicity, 
untransfected 293T cells were plated at a density of 2×10
4
 cells/well in a poly-D-lysine 
96-well plate. The cells were pretreated with various concentrations of Compound D and 
incubated for 21 h. The cells were treated with WST-8 (Cell counting kit-8, Dojindo, 
Kumamoto, Japan) and incubated for 3 h. The absorbance at 450 nm was measured. 
 
IκBα phosphorylation and degradation assays 
HeLa cells (American Type Culture Collection) grown in a 24-well plate in RPMI-1640 
medium supplemented with 10% (v/v) FBS, 50 units/mL of penicillin and 50 μg/mL of 
streptomycin were starved with serum-free medium for 1 day. The cells were pretreated with 
various concentrations of Compound D for 15 min, followed by stimulation with 10 ng/mL of 
TNFα for 10 min (IκBα phosphorylation) or 15 min (IκBα degradation). After washing with 
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Hank’s balanced salt solutions, the cells were lysed with 50 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 7.4), 150 mM NaCl, 30 mM 
Na4P2O7, 50 mM NaF, 1 mM Na3VO4, 1% (v/v) Triton X-100, and EDTA-free protease 
inhibitor cocktail by freeze-thawing. The supernatant was obtained by centrifugation (13,000g 
at 4°C for 5 min) and boiled with Laemmli sample buffer. The proteins were separated using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto 
polyvinylidene fluoride membranes. Blots were blocked with 5% (w/v) BSA in 
tris(hydroxymethyl)aminomethane-buffered saline with 0.1% (v/v) Tween 20 and incubated 
with polyclonal anti-phosphorylated IκBα antibody (Cell Signaling Technologies, Danvers, 
USA) or anti-IκBα antibody (Millipore, Billerica, USA), and subsequently incubated with 
anti-rabbit secondary antibody conjugated with horseradish peroxidase (GE Healthcare, Little 
Chalfont, England). Enhanced chemiluminescence (GE Healthcare) was used for detection. 
 
NF-κB-DNA binding assay 
NF-κB-DNA binding was detected by an electrophoretic mobility shift assay. HeLa cells 
grown in a 24-well plate were starved with serum-free medium for 1 day. The cells were 
pretreated with various concentrations of Compound D for 15 min, followed by stimulation 
with 10 ng/mL of TNFα for 30 min. The cells were harvested and washed with Buffer H (20 
mM HEPES, pH 7.9, 1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid, 2 mM MgCl2, 1 
mM Na3VO4, 20 mM NaF, 1 mM dithiothreitol, 0.1 mM Pefablock and 10 μg/mL of 
leupeptin). After removal of the cytosolic fraction by Buffer H containing 0.2% (v/v) Nonidet 
P-40, a nuclear pellet was vigorously mixed with Buffer H containing 420 mM NaCl and 20% 
(v/v) glycerol for 2 h. The supernatant was obtained by centrifugation (13,000g at 4°C for 5 
min) as nuclear extracts. The nuclear extracts were incubated with 2 units/mL of poly(dI-dC) 
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in 10 mM HEPES, 1 mM EDTA, 50 mM NaCl, 5% (v/v) glycerol and 0.1% (v/v) Nonidet 
P-40 for 30 min, followed by incubation for 30 min with 2 pmol/mL of biotinylated 
oligonucleotides of consensus DNA-binding sites for NF-κB as follows: sense, 
5’-AGCTCAAACAGGGGGCTTTCCCTCCTC-3’; antisense, 
5’-AGCTGAGGAGGGAAAGCCCCCTGTTTG-3’. The samples were separated using 
tris(hydroxymethyl)aminomethane-borate-EDTA gel electrophoresis and transferred onto 
nylon membranes, subsequently crosslinked by UV irradiation. The binding of NF-κB to the 
oligonucleotides was detected using a Chemiluminescent Nucleic Acid Detection Module 
(Thermo Fisher Scientific, Waltham, USA) according to the manufacturer’s instructions. 
 
LPS-induced cytokine production assay using human blood cells 
Human blood cells were obtained from the venous blood of healthy adult volunteers in 
accordance with the ethical approval guidelines of the Daiichi Sankyo Co. Ltd. Ethics Board. 
The blood cells were suspended to 2×10
6
 leukocytes/mL in RPMI-1640 containing 10% FBS, 
25 mM HEPES, 50 units/mL of penicillin and 50 μg/mL of streptomycin. The cells were 
plated in a 96-well plate at a volume of 100 μL/well and pretreated with various 
concentrations of Compound D just before the stimulation with 1 μg/mL of LPS. After 4 h 
(TNFα) or 24 h (IL-6) of incubation at 37°C, the culture supernatants were harvested by 
centrifugation (400g at 4°C for 5 min). The concentrations of TNFα and IL-6 in the 
supernatants were measured using an OptEIA ELISA kit (BD Biosciences) according to the 
manufacturer’s instructions. 
 
LPS-induced TNFα production assay in mice 
BALB/c mice were orally given Compound D or vehicle (0.5% methyl cellulose). After 30 
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min, 0.02 mg/kg of LPS or saline was administered intravenously. After 1 h, blood was 
collected in the presence of heparin and the plasma was obtained by centrifugation (1,000g at 
4°C for 30 min). The concentration of TNFα in the plasma was measured using a Quantikine 
ELISA kit (R&D Systems, Minneapolis, USA) according to the manufacturer’s instructions. 
Plasma concentrations of Compound D were determined by the LC/MS/MS method. 
 
Induction and assessment of CIA in mice 
DBA/1J mice were immunized by an intradermal injection at the base of the tail with 0.1 mL 
of emulsion containing 1.5 mg/mL of bovine CII (Collagen Gijutsu-Kenshukai) in Freund’s 
complete adjuvant. Twenty-one days later, the mice were secondarily immunized by an 
intradermal injection at the abdomen with a total of 0.1 mL of the emulsion. Compound D 
was orally administered once daily beginning with the day of the 2
nd
 immunization for 14 
days and all paws of the mice were obtained for measurement of gene expression 24 h after 
final administration at 14 days after the 2
nd
 immunization. For the evaluation of the efficacy 
of the compound administered after disease development, Compound D was orally 
administered once daily from 5 days after the 2
nd
 immunization for 12 days. For 
pharmacokinetics and gene expression analyses in a single oral administration of the 
compound, Compound D was orally administered to CIA mice 9-10 days after the 2
nd
 
immunization. The plasma and paws were obtained at the indicated time after administration, 
and gene expression and the concentration of the compound in the tissues were measured. 
Total RNA was extracted from the paws that had been homogenized in ISOGEN (Nippon 
gene) using Polytron and reverse transcribed to cDNA using SuperScript III First-Strand 
Synthesis Super Mix (Life Technologies). A PCR was performed using a 7500 real-time PCR 
system (Life Technologies) with TaqMan Gene Expression Assays (Life Technologies) and 
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Premix Ex-Taq (Takara Bio) according to the manufacturer’s instructions. The mRNA 
expression levels were normalized with each GAPDH expression level. The concentrations of 
the compound in the tissues were determined by the LC/MS/MS method. The severity of 
arthritis of each paw was scored periodically on a scale of 0-3 according to the following 
criteria: 0, normal; 0.5, swelling of one digit; 1, swelling of more than two digits or redness of 
paw; 2, swelling of part of paw; and 3, swelling of entire paw. 
 
Statistical analysis 
The data are expressed as mean ± standard deviation (SD) or mean ± SE. Statistical 
significance in the comparison of TNFα production and gene expressions was determined by 
a parametric Dunnett’s test. Statistical significance in the comparison of arthritis scores was 
determined by a nonparametric Dunnett’s test. 
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Results 
 
Compound D is a selective inhibitor of IKKβ 
Compound D (Figure 5A; page 81) was identified as a potent small molecule inhibitor of 
IKKβ from the chemical optimization of a series of imidazo[1,2-b]pyridazine derivatives 
discovered by high-throughput screening of chemical libraries (Shimizu et al., 2010; Shimizu 
et al., 2011a; Shimizu et al., 2011b). To evaluate the kinase selectivity of Compound D, I 
determined the 50% inhibitory concentration (IC50) values against IKKβ and related kinase 
IKKα. Compound D inhibited kinase activities of IKKβ and IKKα with an IC50 of 0.037 and 
6.1 μM, respectively, and demonstrated 164-fold selectivity (Figure 5B; page 81). 
 To examine the selectivity of Compound D in cellular signaling pathways, I 
performed the reporter assays that represent major signaling pathways using 293T cells. 
Compound D inhibited NF-κB promoter activity with an IC50 of 0.15 μM, while the 
compound weakly inhibited promoter activities of other pathways, showing over 100-fold 
selectivity compared to the NF-κB pathway (Table 3; page 71). In addition, 20 μM of the 
compound did not cause 50% inhibition of the cell viability at 24 h (Table 3; page 71). 
 
Compound D inhibits the NF-κB signaling pathway 
To confirm whether Compound D inhibits the IKK-mediated signal transduction to NF-κB, I 
performed IκBα phosphorylation and degradation assays and an NF-κB-DNA binding assay 
using HeLa cells. Compound D inhibited IκBα phosphorylation and subsequent degradation 
induced by TNFα in a concentration-dependent manner (Figure 6A; page 82). Additionally, 
Compound D inhibited NF-κB-DNA binding as well (Figure 6B; page 82). The IC50 values 
against these signals were in the range of 0.1 to 1 μM, which were comparable to that against 
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NF-κB promoter activity. 
 
Compound D inhibits NF-κB-driven cytokine production 
LPS is known to induce NF-κB-driven production of proinflammatory cytokines such as 
TNFα and IL-6 (Guha and Mackman, 2001). To examine whether Compound D inhibits 
NF-κB-driven production of proinflammatory cytokines other than TNFα, I performed 
LPS-induced IL-6 production assay using human blood cells. Compound D inhibited the 
productions of TNFα and IL-6 comparably (Figure 7A; page 83). The calculated IC50 values 
were 0.22 and 0.27 μM, respectively. Thus, Compound D inhibited NF-κB-driven production 
of multiple proinflammatory cytokines. In addition, The IC50 value for TNFα was consistent 
with that in mouse blood cells with an IC50 of 0.23 μM as described in the previous report 
(Shimizu et al., 2011a), indicating that Compound D had no species difference between 
humans and mice in its inhibitory activity on LPS-induced TNFα production. 
 
The inhibition of TNFα production correlates with the plasma concentration of 
Compound D in vivo 
To examine the relationship between the effect on cytokine production and plasma 
concentration of Compound D, I performed an LPS-induced TNFα production assay in vivo. 
The mice were pretreated with Compound D for 30 min, followed by an LPS injection, and 1 
h later, blood was collected to measure the TNFα and Compound D levels. Orally 
administered Compound D inhibited LPS-induced TNFα production in a dose-dependent 
manner (Figure 7B; page 83). Compound D inhibited 30% of TNFα production with a dose 
of 10 mg/kg, and completely inhibited it with a dose of 100 mg/kg. The concentrations of 
Compound D in the plasma 1.5 h after administration were 0.39, 2.9 and 9.4 μM at doses of 
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10, 30 and 100 mg/kg, respectively, showing dose-dependent elevation (Table 4; page 72). 
Thus, the inhibition of TNFα production correlated with the plasma concentration of 
Compound D in vivo. 
 
Compound D inhibits expression of proinflammatory cytokines in arthritic paws by 
consecutive treatment 
Compound D is efficacious in experimental arthritis models as described previously (Shimizu 
et al., 2011a). However, the molecular mechanisms of the anti-arthritic effect remain unclear. 
To investigate the mechanisms, I analyzed the arthritic paws of the compound-administered 
CIA mice in detail. First, to confirm the efficacy of Compound D, multiple dosages of 
Compound D or vehicle were administered once daily beginning with the day of the 2
nd
 
immunization for 14 days and the severity of arthritis was scored periodically. As shown in 
Figure 8A (page 84, 85), Compound D significantly decreased the mean arthritis scores in a 
dose-dependent manner. The repeated administration of the compound did not affect body 
weight gain (Figure 8B; page 84, 85). Considering the inhibitory effect of LPS-induced TNFα 
production in vivo by Compound D, it is suggested that one of the mechanisms of its efficacy 
in CIA is downregulation of proinflammatory cytokines in the arthritic paws. To examine this, 
I measured the gene expression levels of proinflammatory cytokines and other inflammatory 
mediators associated with RA in the arthritic paws. The paws of CIA mice were harvested 24 
h after final administration at 14 days after the 2
nd
 immunization and the gene expression 
levels were measured by quantitative PCR. I measured the mRNA levels of proinflammatory 
cytokines, TNFα, IL-1β and IL-6, and various mediators related to the destruction of bone and 
cartilage, RANKL, MMP-3 and MMP-9. The arthritic mice administered with only vehicle 
displayed higher levels of the mRNA expressions of the proinflammatory cytokines and 
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inflammatory mediators compared to disease-free normal mice (Table 5; page 73). In contrast, 
the expression levels of the genes, except for TNFα, tended to be low in Compound D-treated 
mice (Table 5; page 73). Although due to the considerable variation it did not reach statistical 
significance, the expression levels decreased in dose-dependent manner. Taken together, these 
data suggest the possibility that the consecutive treatment of Compound D inhibits the gene 
expression of proinflammatory cytokines and inflammatory mediators in the arthritic paws of 
CIA mice. 
 
Compound D distributes to arthritic paws and downregulates proinflammatory 
cytokines 
I investigated the relationship between pharmacokinetics and the inhibition of gene 
expression by Compound D in arthritic mice. Compound D levels in plasma and paws of 
normal and arthritic mice were measured at the indicated time after oral administration of the 
compound at a dosage of 30 mg/kg. In the normal mice, Compound D levels in both plasma 
and paw tissue decreased from 1 h after administration and disappeared at 24 h. In contrast, 
Compound D in the arthritic paws was detected at a higher level compared to plasma, which 
remained at more than 1,000 pmol/g at 24 h, while the plasma compound level of arthritic 
mice exhibited only slight elevation compared to normal mice (Figure 8C; page 84, 85). 
These data indicates that Compound D distributes to the arthritic paws compared to healthy 
paws. 
 I further investigated whether Compound D functions in the arthritic paws because 
the consecutive treatment has a potential to affect various cells and organs. To exclude the 
indirect effect of Compound D on gene expression of proinflammatory cytokines in arthritic 
paws, I measured the mRNA levels of TNFα and IL-1β in the paws of CIA mice 2 h after a 
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single oral administration of the compound. The gene expression levels of TNFα and IL-1β in 
the arthritic paws were elevated compared to normal mice, and Compound D decreased the 
gene expression levels of TNFα and IL-1β at a dose of 100 mg/kg (Figure 8D; page 84, 85). 
The Compound D levels in the paws 2 h after administration at dosages of 30 and 100 mg/kg 
were 1,166 ± 554 and 24,727 ± 3,594 pmol/g (mean ± SD), respectively, showing rapid 
distribution of the compound into the arthritic paws in a dose-dependent fashion. These data 
indicates that Compound D rapidly distributes to the arthritic paws and where the compound 
directly downregulated the gene expression of proinflammatory cytokines. 
 
Compound D inhibits arthritis progression by the treatment after disease development 
Finally, to evaluate the efficacy of Compound D administered after disease development, the 
compound was orally administered once daily from 5 days after the 2
nd
 immunization for 12 
days and arthritis scores were periodically measured. As shown in Figure 8E (page 85), 
Compound D at a dosage of 100 mg/kg completely inhibited the progression of arthritis under 
the treatment during this experiment. 
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Discussion 
 
In the present study, I validated the selectivity of Compound D in the inhibition of IKKβ 
kinase activity and the blockade of the NF-κB signaling pathway. In addition, I confirmed the 
concentration-dependent inhibition of NF-κB-driven production of proinflammatory 
cytokines by Compound D in vitro and in vivo. Furthermore, I demonstrated that Compound 
D preferentially distributes to arthritic paws compared to healthy paws and where it 
downregulates proinflammatory cytokines in the arthritic joints. 
 The results of the in vitro analyses demonstrate that Compound D is a selective 
inhibitor of IKKβ. Compound D inhibited IKKβ kinase activity with an IC50 of 0.037 μM 
with 160-fold selectivity against related kinase IKKα. Studies using genetically manipulated 
mice implied that IKKβ, but not IKKα, was a key driver of NF-κB activation (Li et al., 1999; 
Ghosh and Karin, 2002); therefore, high selectivity for IKKβ over IKKα should be effective 
for the downregulation of proinflammatory cytokines in inflammatory conditions where 
NF-κB is preferentially activated. The NF-κB pathway mediated by IKKβ is activated in 
response to inflammatory stimuli, such as TNFα and IL-1, leading to IκB phosphorylation, 
subsequent IκB degradation, NF-κB nuclear translocation and DNA binding (DiDonato et al., 
1996; Karin, 1999). Compound D inhibited TNFα-induced IκBα phosphorylation, degradation 
and NF-κB-DNA binding in HeLa cells in a concentration-dependent fashion with 
comparable inhibitory potency against NF-κB promoter activity in 293T cells (Table 3). 
Although the inhibitory activities of Compound D in the cellular assays were 10 times lower 
than that in the kinase assay, the reduction in the activity is reasonable because over 90% of 
the compound may bind to serum proteins in the cellular assays containing 10% FBS, as 
suggested by its protein binding property (Shimizu et al., 2011a). These findings suggest that 
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the blockade of the NF-κB pathway by Compound D is due to its inhibitory activity of IKKβ. 
Notably, Compound D affected pathways other than the IKKβ/NF-κB pathway only at high 
concentrations more than 100-fold. These results indicate that Compound D selectively blocks 
the NF-κB pathway among major cellular pathways. Compound D did not change the cell 
viability at even 100-fold concentration of NF-κB inhibition. These findings suggest that the 
high selectivity of Compound D could contribute to fewer side effects. 
 LPS activates the NF-κB signaling pathway mediated by IKKβ (Hawiger et al., 1999; 
Guha and Mackman, 2001). Compound D potently inhibited TNFα productions in a 
concentration-dependent manner in LPS-stimulated human blood cells in vitro and 
LPS-injected mice in vivo. The effective plasma concentrations in vivo (Table 4; page 72) are 
likely to correlate with the inhibitory concentrations in human blood cells in vitro. As 
expected, the inhibitory concentration range on TNFα production in human blood cells was 
comparable to that of NF-κB promoter activity as well as the signal transduction to NF-κB in 
HeLa cells. Consistent with this, Compound D inhibited production of IL-6, one of the 
proinflammatory cytokines regulated by NF-κB, as potently as TNFα in human blood cells. 
These findings suggest that the inhibition of the cytokine production is based on the blockade 
of the NF-κB pathway via IKKβ inhibition. These inhibitory profiles of Compound D should 
contribute its efficacy in inflammatory conditions such as arthritis where multiple 
proinflammatory cytokines are simultaneously elevated (Houssiau et al., 1988; Tetta et al., 
1990). 
 Compound D displayed a unique pharmacokinetic feature manifested as preferential 
distribution to arthritic paws compared to healthy paws. Previous studies have shown that 
vascular permeability increased preferentially in the arthritic joints (Binstadt et al., 2006; 
Blanchet et al., 2010; Cloutier et al., 2012). This enhanced vascular permeability has been 
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associated with mast cells, neutrophils and endothelial cells in response to immune complexes 
in the joints (Binstadt et al., 2006). These findings suggest that Compound D may 
preferentially distribute to the arthritic paws by immune complex-triggered alterations in the 
local joint environment. Notably, Compound D retained in the arthritic paws at a higher level 
even though the compound disappeared from plasma. The retention period of Compound D 
seems to be much longer in comparison with other small-molecular agents, such as 
methotrexate (Stewart et al., 1987). This finding suggests that the mechanisms of the 
characteristic tissue localization of Compound D would depend on its chemical property. It is 
probable that the compound binds to arthritic joint contents such as joint structural 
components, inflammation-induced proteins and immune complexes. 
 The consecutive treatment of Compound D resulted in reduction of the gene 
expression of proinflammatory cytokines and inflammatory mediators in the paws of CIA 
mice, accompanied with the dose-dependent efficacy to the disease. Although Compound D 
did not markedly decrease TNFα gene expression compared to the other genes in the 
experiment of consecutive treatment (Table 5; page 73), the compound resulted in reduction 
of the gene expression of TNFα as well as IL-1β in the established arthritic paws after 2 h of a 
single administration. It is known that TNFα plays an important role only in the development 
of CIA at an early stage and its expression is reduced in late stages of the disease (Williams et 
al., 1992; Wooley et al., 1993; Joosten et al., 1996). Indeed, the TNFα mRNA level was low at 
the time point used in my present study, consistent with previous reports (Rioja et al., 2004; 
Medicherla et al., 2006). These observations imply that the elevation of TNFα expression 
might be too low to evaluate the inhibitory effect of the compound even though the expression 
is higher than unimmunized normal mice. Alternatively, it is possible that TNFα expression 
has recovered at the vehicle-treated level at 24 h after administration due to the decline of the 
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concentration of the compound in the paw, even though the expression was inhibited 2 h after 
administration as observed in the present study. This is because TNFα expressed more rapidly 
than other cytokines by proinflammatory stimulation in the paws (Marinova-Mutafchieva et 
al., 1997; Thornton et al., 1999; Kagari et al., 2002). Nevertheless, the efficacy of Compound 
D was observed despite upregulation of the TNFα expression. In contrast, the other genes may 
be continuously downregulated at least until 24 h after administration and thereby markedly 
suppressed by the consecutive treatment. Consistent with this, Compound D completely 
inhibited arthritis progression even when treatment occurred after disease development, 
suggesting that the downregulation of proinflammatory cytokines in the arthritic joints 
contributes to the anti-arthritic effect.  
 The treatment of Compound D reduced gene expression of inflammatory mediators 
involved in the destruction of bone and cartilage, such as RANKL, MMP-3 and MMP-9, as 
well as proinflammatory cytokines in the paws of CIA mice (Table 5; page 73). MMP-3 and 
MMP-9, which are overexpressed as a result of aspects of joint inflammation such as 
proliferation of synovial cells and infiltration of inflammatory cells, degrade the extracellular 
matrix and cartilage (Yoshihara et al., 2000; Goldring and Marcu, 2009). MMPs were 
detected at high levels in the synovial fluid or serum of RA patients (Yoshihara et al., 2000; 
Tchetverikov et al., 2004). RANKL is known to contribute to bone erosion and destruction by 
differentiation and activation of osteoclasts (Goldring, 2002). Suppression of bone destruction 
by Compound D was observed in the rat arthritis model, accompanied with delayed onset and 
relieved symptoms of paw swelling (Shimizu et al., 2011a). Based on these findings, 
Compound D has a potential to suppress the destruction of bone and cartilage in RA. 
 CIA is commonly used as an RA model because of its similarities in both etiology 
and pathology (Williams, 2007). In the joint tissue of CIA mice, synovial hyperplasia and 
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infiltration of inflammatory cells have been observed (Williams, 2007). These synovial cells 
secrete proinflammatory cytokines, which amplify inflammation through further generation of 
various inflammatory mediators. Involvement of proinflammatory cytokines in the 
pathogenetic process of CIA is evident by the effectiveness of neutralizing antibodies against 
TNFα, IL-1β and IL-6 (Williams et al., 1992; Takagi et al., 1998; Williams et al., 2000). 
Additionally, NF-κB activation has been demonstrated in the synovial tissue of mice in the 
development of CIA (Tak and Firestein, 2001; Podolin et al., 2005). The intra-articular gene 
transfer of wild-type IKKβ into the joints of normal rats causes paw swelling and synovial 
inflammation, while the transfer of a dominant-negative IKKβ ameliorates the severity of 
adjuvant arthritis (Tak and Firestein, 2001). These findings suggest that IKKβ plays an 
important role in synovial inflammation in arthritic joints. The role of IKKβ in inflammatory 
diseases has been demonstrated in multiple disease-relevant cells and animal models using 
selective IKKβ inhibitors (McIntyre et al., 2003; Podolin et al., 2005; Schopf et al., 2006; 
Mbalaviele et al., 2009; Gamble et al., 2012). However, the mechanisms of the action of 
IKKβ inhibitors are complicated because NF-κB plays an important role in immune response, 
inflammation, cell differentiation, proliferation and survival in various cells and tissues 
(Baeuerle and Henkel, 1994; Hayden and Ghosh, 2004; Perkins, 2007). An IKKβ inhibitor 
could induce a variety of functional alterations in various cells through suppression of the 
NF-κB signaling as contribution to the efficacy or other side effects, in addition to inhibiting 
proinflammatory cytokine productions in arthritic joints. In this regard, Compound D may be 
a useful agent for understanding the mechanisms of the anti-arthritic effect of IKKβ inhibitors 
in arthritic joints because Compound D may function in local inflammatory sites due to its 
preferential distribution in the arthritic paws compared to healthy ones. Supporting this, 
Compound D did not affect the body weight gain of arthritic mice by consecutive treatment, 
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implying the compound has less systemic toxicity. The inhibitory activity of Compound D 
against generation of proinflammatory cytokines in the arthritic joint tissue could be led by a 
blockade of the NF-κB pathway through IKKβ inhibition and break the amplification loop of 
inflammation in CIA. Taking these findings together, one of the mechanisms underlying the 
anti-arthritic effect of Compound D should be the direct downregulation of proinflammatory 
cytokines in the arthritic joints. 
 In summary, I have characterized a novel small molecule IKKβ inhibitor, Compound 
D, exhibiting selective inhibition of the IKKβ kinase activity and the NF-κB signaling 
pathway. Furthermore, I have demonstrated that Compound D preferentially distributed to the 
arthritic paws, compared to healthy paws, where it directly downregulated the gene 
expression of proinflammatory cytokines, thereby exhibiting an anti-arthritic effect. These 
findings suggest that NF-κB-dependent proinflammatory cytokines in local joint tissues play 
an important role on the development of CIA. 
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In the present study, in order to elucidate the role of proinflammatory cytokines in joint 
tissues during development of arthritis, I analyzed pathogenetic mechanisms of LPS-induced 
exacerbation of arthritis and the role of NF-κB in the regulation of proinflammatory cytokines 
expression in joint tissues using a mouse CIA model. Recently, studies of development and 
pathophysiology of RA are performed on the experimental arthritis models applied to several 
kinds of knockout mice to clarify the role of the target genes. In such cases, emphasis tends to 
be placed on characterization of phenotypes; thereby molecular mechanisms before the onset 
of the disease have been poorly investigated. In addition, immunity is established by the 
network formed by a variety of immune cells interacting with each other in the whole body; 
therefore, it is difficult to analyze tissue-specific mechanisms. From these aspects, a 
spatiotemporal-specific approach is necessary to gain further insight into the mechanisms of 
RA. Therefore, I focused on the mechanisms specifically in local joint tissues during 
development of arthritis. 
 I demonstrated in the present study that the timing of the expression of 
proinflammatory cytokines, such as TNFα and IL-1β, in the joint tissues of LPS-CIA mice 
was accelerated; nevertheless, the sequence was likely consistent with other animal arthritis 
models (Marinova-Mutafchieva et al., 1997; Thornton et al., 1999; Rioja et al., 2004). I also 
demonstrated here that these proinflammatory cytokines are regulated by NF-κB in arthritic 
joint tissues and contributed to the progression of arthritis. In particular, the expression 
pattern of TNFα was implicated as a key factor in the early stages of arthritis development as 
previously reported (Joosten et al., 1996). Especially, the mechanism of production of anti-CII 
antibodies induced by TNFα is of great interest. Recombinant TNF receptor Fc fusion protein 
inhibited anti-collagen antibody production in CIA mice (Wooley et al., 1993), supporting 
involvement of TNFα in the mechanism on anti-collagen antibody production. The 
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mechanisms can be explored by studying B cells in vitro in the future. The study also raises 
the possibility that involvement of other proinflammatory cytokines could be necessary for 
the development of LPS-CIA because TNFα injection accompanied by subsequent increase of 
anti-CII antibodies is not sufficient to induce arthritis. It has been reported that the injection of 
IL-1β is able to accelerate CIA (Caccese et al., 1992). Therefore, TNFα and IL-1β, although 
having similar properties, act in distinctive manners to develop arthritis. Additionally, MIP-2 
could play an important role in the recruitment of neutrophils, which is highlighted as a 
possible contributor in the early phases of RA and animal arthritis models (Thornton et al., 
1999; Wipke and Allen, 2001; Tanaka et al., 2006; Cascao et al., 2010; Wright et al., 2010; 
Dominical et al., 2011). Notably, NF-κB also regulates the gene expression of MIP-2 (Kim et 
al., 2003). The proinflammatory cytokines activate inflammatory cells including synovial 
cells, and induce production of autoantibodies and inflammatory mediators, such as cytokines, 
chemokines and proteases. The inflammatory responses induce further production of 
proinflammatory cytokines through formation of immune complexes and recruitment of 
inflammatory cells into the synovium. Their interplay might promote the generation of 
inflammatory loop responsible for progression of joint inflammation. Taken together, 
proinflammatory cytokines regulated by NF-κB in local joint tissues are one of the key factors 
in the development of arthritis via amplification of joint inflammation through acceleration of 
the inflammatory loop. 
 The NF-κB signaling pathway is important and necessary to the mechanisms 
underlying the function and pathogenesis of arthritis; however, the idea to apply NF-κB 
inhibitors, such as IKKβ inhibitors, for the therapy of RA is not yet validated. One of the 
reasons is that the systemic inhibition of the NF-κB pathway by chemicals should lead to 
tremendous numbers of side effects throughout the body because the NF-κB signaling 
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pathway functions in a variety of mammalian tissues other than pathogenic cells in patients 
with RA (Tak and Firestein, 2001; Senftleben and Karin, 2002; Viatour et al., 2005; Brown et 
al., 2008). Therefore, a rational approach is necessary to use the NF-κB inhibitor as a 
beneficial drug for a specific disease. Based on the findings in the present study, regulation of 
IKKβ in locally inflamed joint tissues may be a promising approach for the therapeutics of 
RA. Although several small molecule inhibitors of IKKβ have been identified, and the 
efficacy of each inhibitor has been clearly demonstrated in arthritis models (McIntyre et al., 
2003; Podolin et al., 2005; Schopf et al., 2006; Mbalaviele et al., 2009), there is no report on 
IKKβ inhibitors which have been analyzed from the perspective of the relationship between 
the distribution of the compounds in tissue and the regulation of proinflammatory cytokines in 
the arthritic joints. In this regard, Compound D may be a useful agent because the compound 
may function in local inflammatory sites due to its preferential distribution in the arthritic 
paws compared to healthy ones. 
 In conclusion, I demonstrated that the NF-κB-dependent proinflammatory cytokines 
in local joint tissues amplify inflammation and contribute to the development of arthritis 
(summarized in Figure 9; page 86). 
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Table 1  Fold change of mRNA of inflammatory mediators on Days 3 and 6. 
 
 
 
 
 
 
 
The experiment was performed as described in the legend to Figure 2A. The data are 
expressed as mean ± SE of fold changes over pre-LPS injection (n, pre = 8, the others = 12). 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; vs. pre-LPS group by a Dunnett’s test. 
Gene Day 3  Day 6 
IL-1 8.0  2.2  21.5  2.8 *** 
IL-6 21.2  8.8  32.9  6.6 * 
IL-17A 7.2  2.6  13.0  2.9 ** 
RANKL 5.9  1.2  20.4  2.7 *** 
MIP-2 4.9  1.6  16.4  2.8 *** 
MMP-3 14.2  3.8  48.3  6.9 *** 
MMP-9 2.3  0.5  19.5  2.5 *** 
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Table 2  Correlation between arthritis scores and expression level of inflammatory 
mediators. 
 
 
The experiment was performed as described in the legend to Figure 2B. The data are 
expressed as mean ± SE of relative expression values against each GAPDH expression level  
(n, score 0 = 8, score 1 = 12, scores 2 and 3 = 6). The correlations between the mRNA levels 
and arthritis scores are determined using a Spearman's rank order correlation test. R, 
correlation coefficient (***, P < 0.001). 
Gene Score 0 Score 1 Score 2 Score 3  R 
IL-1 0.1 ± 0.0 0.7 ± 0.2 1.3 ± 0.5 2.1 ± 0.9  0.82 *** 
IL-6 0.1 ± 0.0 1.3 ± 0.4 1.4 ± 0.6 3.0 ± 1.2  0.75 *** 
IL-17A 0.1 ± 0.0 0.3 ± 0.1 0.7 ± 0.3 1.4 ± 0.6  0.62 *** 
RANKL 0.0 ± 0.0 0.3 ± 0.1 0.6 ± 0.3 1.2 ± 0.5  0.84 *** 
MIP-2 0.1 ± 0.0 0.2 ± 0.1 0.6 ± 0.3 1.6 ± 0.6  0.79 *** 
MMP-3 1.3 ± 0.5 8.5 ± 2.4 10.0 ± 4.1 26.3 ± 10.7  0.89 *** 
MMP-9 0.6 ± 0.2 2.8 ± 0.8 5.6 ± 2.3 12.3 ± 5.0  0.78 *** 
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Table 3  Signaling pathway selectivity of Compound D in reporter assay. 
 
 
 
 
 
 
293T cells transfected with each reporter luciferase plasmid were treated with various 
concentrations of Compound D and stimulated with each stimulant as described in Materials 
and Methods. After 6 h (TNFα) or 24 h (the others), the luciferase activities were measured. 
Viability of untransfected 293T cells treated with Compound D was evaluated at 24 h using 
WST-8. 
Target  IC50 (μM)
 
NF-κB  0.15 
AP-1  >20 
NFAT  >20 
SRE  19 
CRE  >20 
ISRE  16 
Viability (24 h)  >20 
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Table 4  Concentrations of Compound D in the plasma 1.5 h after a single oral 
administration. 
 
 
 
 
The experiment was performed as described in the figure legend to Figure 7B. The data are 
expressed as mean ± SD of five mice in each group. 
Dose (mg/kg) 
Plasma concentration of 
Compound D (μM) 
10 0.39  0.18 
30 2.9  0.95 
100 9.4  4.3 
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Table 5  Gene expressions in paws of CIA mice after the consecutive treatment of 
Compound D. 
 
The experiment was performed as described in the figure legend to Figure 8A. Gene 
expressions in the paws of CIA mice 14 days after the 2
nd
 immunization are shown as relative 
expression values against each GAPDH expression level. The data are expressed as mean ± 
SE of seven mice in each group. No values were statistically significant compared to 
vehicle-treated group (P > 0.05, by a parametric Dunnett’s test). 
Gene 
Normal Arthritis Arthritis Arthritis 
 + Vehicle 
+ 30 mg/kg  
Compound D  
+ 100 mg/kg  
Compound D  
TNFα 0.03 ± 0.01 0.47 ± 0.19 0.49 ± 0.20 0.27 ± 0.09 
IL-1β 0.01 ± 0.01 2.55 ± 1.36 0.59 ± 0.35 0.53 ± 0.26 
IL-6 0.00 ± 0.00 4.79 ± 3.07 0.47 ± 0.26 0.26 ± 0.11 
RANKL 0.00 ± 0.00 2.13 ± 1.34 0.34 ± 0.20 0.13 ± 0.10 
MMP-3 0.00 ± 0.00 2.29 ± 1.12 0.54 ± 0.33 0.21 ± 0.08 
MMP-9 0.00 ± 0.00 6.80 ± 4.05 1.14 ± 0.76 0.72 ± 0.34 
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Figure 1  Time course of arthritis development induced by an LPS injection in 
CII-immunized mice. The mice were injected with LPS or saline 17 days after CII 
immunization. Arthritis severity and histopathology were periodically evaluated. (A) Arthritis 
scores are expressed as mean ± SE of five (saline) or ten (LPS) mice in each group. (B) 
Prevalence of paw inflammation is expressed as a percentage of the number of mice in each 
group with at least one affected paw. (C) Histopathological scores of tarsal joints. The data are 
expressed as mean + SE (n = 3). *, P < 0.05; **, P < 0.01; vs. normal group by a 
nonparametric Dunnett’s test. (D-I) Representative histologies of synovium (D-F) and bone 
and cartilage (G-I) of the tarsal joints stained with hematoxylin and eosin of normal mice (D, 
G), LPS-CIA mice on Day 3 (E, H) and Day 7 (F, I). Neutrophils (n), edema (e), synovial cell 
(s) and bone destruction (arrowhead) are indicated. Original magnification, (D-F) 200, (G, 
H) 100, (I) 40. (F) is a photograph of the inset in (I) at higher magnification. Scale bars, 100 
μm. 
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Figure 2  Gene expression level in paws of LPS-CIA mice. Expression levels of various 
mRNAs in the paws of LPS-CIA mice were measured by quantitative real-time PCR in 
specimens obtained pre- or on various days after LPS injection. The data were normalized 
with expression level of GAPDH. (A) The mRNA level of TNF on pre-LPS injection, at 6 h, 
and on Days 3 and 6. The data are expressed as mean + SE of fold changes over pre-LPS 
injection (n, pre = 8, the others = 12). *, P < 0.05; **, P < 0.01; vs. pre-LPS group by a 
Student’s t-test. (B) Correlation between arthritis scores and expression level of mRNA of 
TNF on Days 0, 3 and 6. Horizontal bars represent the mean of mRNA expression for each 
score (n, score 0 = 8, score 1 = 12, scores 2 and 3 = 6). The R-values represent Spearman’s 
rank order correlation coefficients. (C-E) The mRNA levels of IB and inflammatory 
mediators at indicated times after LPS injection. The data are expressed as mean + SE of fold 
changes over pre-LPS injection (n = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001; no asterisk, 
not significant vs. pre-LPS group by a parametric Dunnett’s test. 
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Figure 3  Serum anti-CII antibody concentrations in LPS-CIA mice. Serum was obtained at 
the indicated time points after LPS injection. Anti-CII IgG concentrations in the serum were 
measured by ELISA. (A) Anti-CII IgG concentrations 6 days after LPS or saline injection. 
The data are expressed as mean + SE (n = 6). NS, not significant vs. pre-LPS group by a 
Student’s t-test. (B) Anti-CII IgG concentrations at indicated times after LPS injection. The 
data are expressed as mean + SE (n = 5). *, P < 0.05; vs. pre-LPS group by a parametric 
Dunnett’s test. ND, not detected. 
A B 
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Figure 4.  Involvement of TNFα in development of LPS-CIA. (A, B) Recombinant mouse 
TNFα was injected into CII-immunized mice. Arthritis scores (A) and serum anti-CII IgG 
concentrations (B) on Day 6 are expressed as mean + SE (n, normal = 8, 20 ng/kg TNFα = 5, 
the others = 6). NS, not significant; vs. normal group by a nonparametric Dunnett’s test, †††, P 
< 0.001; vs. normal group by a Wilcoxon's rank sum test, *, P < 0.05; **, P < 0.01; vs. normal 
group by a parametric Dunnett’s test. ND, not detected. (C) Anti-TNFα antibodies or control 
IgG (25 mg/kg) were administered intraperitoneally once daily from the day before to 6 days 
after LPS injection. Arthritis scores are expressed as mean ± SE (n = 9). *, P < 0.05; vs. 
control IgG group by a Wilcoxon’s rank sum test.
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Figure 5  Compound D is a selective inhibitor of IKKβ. (A) Chemical structure of 
Compound D. (B) Inhibition of kinase activities of IKKβ and IKKα measured by an IMAPTM 
assay using ATP at the concentrations around Km for each kinase. The data are expressed as 
the mean percentage of inhibition over the vehicle control group. 
A B 
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Figure 6  Compound D inhibits the NF-κB signaling pathway. (A) Inhibition of IκBα 
phosphorylation and degradation induced by TNFα. HeLa cells were starved with serum-free 
medium for 1 day and pretreated with or without Compound D, followed by stimulation with 
10 ng/mL of TNFα for 10 min (IκBα phosphorylation) or 15 min (IκBα degradation). 
Phosphorylated IκBα (upper panel) and total IκBα (lower panel) in the cell lysates were 
detected by Western blotting. (B) Inhibition of NF-κB-DNA binding induced by TNFα. HeLa 
cells prepared and pretreated with Compound D as described above were stimulated with 10 
ng/mL of TNFα for 30 min. Nuclear extracts were prepared and NF-κB-DNA binding was 
detected by an electrophoretic mobility shift assay. 
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Figure 7  Compound D inhibits LPS-induced production of proinflammatory cytokines in 
vitro and in vivo. (A) Inhibition of cytokine production in human blood cells. The blood cells 
from healthy adult volunteers were incubated with 1 μg/mL of LPS for 4 h (TNFα) or 24 h 
(IL-6) in the presence or absence of Compound D. TNFα and IL-6 concentrations in the 
supernatants were measured. The data are shown as a percentage over the vehicle control 
group and expressed as mean + SD of three independent experiments. (B) Inhibition of TNFα 
production in vivo. BALB/c mice were orally given Compound D or vehicle for 30 min, 
followed by an injection of 0.02 mg/kg of LPS, and 1 h later, the plasma was collected to 
measure TNFα levels. The data are expressed as mean + SD of ten (vehicle) or five 
(Compound D) mice in each group. **, P < 0.01; ***, P < 0.001; vs. vehicle-treated group by 
a parametric Dunnett’s test. 
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Figure 8  Compound D inhibits CIA in association with downregulation of proinflammatory 
cytokines in arthritic paws. DBA1/J mice were immunized with CII, and followed 21 days 
later by a 2
nd
 immunization with CII. (A, B) Compound D or vehicle was orally administered 
once daily from the day of the 2
nd
 immunization to Day 13. Arthritis scores (A) and body 
weight gains (B) are expressed as mean ± SE of seven mice in each group. *, P < 0.05; **, P 
< 0.01, vs. vehicle-treated group by a nonparametric Dunnett’s test. (C) Pharmacokinetic 
analyses of Compound D (30 mg/kg) in normal and CIA mice (10 days after the 2
nd
 
immunization). The plasma and paws were collected at indicated times after a single oral 
administration of Compound D to measure the compound levels. The data are expressed as 
mean ± SD of three (normal) or five (arthritic) mice in each group. (D) Gene expressions of 
proinflammatory cytokines in the paws of arthritic mice treated with a single dosing of 
Compound D. The paws of CIA mice (9 days after the 2
nd
 immunization) were obtained 2 h 
after oral administration of Compound D. Gene expressions of TNFα and IL-1β in the paw 
homogenates were measured by quantitative PCR and shown as relative expression values 
against each GAPDH expression level. The data are expressed as mean + SE of five mice in 
each group. *, P < 0.05; ***, P < 0.001; vs. vehicle-treated group by a parametric Dunnett’s 
test. (E) Compound D or vehicle was orally administered once daily from 5 days after the 2
nd
 
immunization to Day 16 and arthritis severities were scored periodically. The data are 
expressed as mean ± SE of seven mice in each group. *, P < 0.05; **, P < 0.01, vs. 
vehicle-treated group by a nonparametric Dunnett’s test. 
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Figure 9  Summary of the role of proinflammatory cytokines in joint tissues during 
development of arthritis. Immune complexes formed with autoantibodies induce recruitment 
and activation of inflammatory cells, such as neutrophils and macrophages, into the synovium. 
These infiltrated inflammatory cells produce proinflammatory cytokines, such as TNFα, IL-1β, 
IL-6 and IL-17A, which activate inflammatory cells including synovial cells. The synovial 
cells proliferate and progress to hyperplasia. The proinflammatory cytokines also induce 
further production of autoantibodies and inflammatory mediators, such as cytokines, 
chemokines and proteases including MMPs and RANKL, which contribute to destruction of 
bone and cartilage. The present study has demonstrated that the proinflammatory cytokines in 
the joint tissues are regulated by NF-κB and involved in amplification of joint inflammation 
(blue arrows). The proinflammatory cytokines, in particular TNFα, in addition to anti-CII 
antibodies are rapidly induced during LPS-induced exacerbation of arthritis. TNFα may 
contribute in the production of anti-CII antibodies. Chemokine MIP-2 is also upregulated in 
association with neutrophil infiltration in the onset of arthritis. Taken together, the 
NF-κB-dependent proinflammatory cytokines in arthritic joint tissues are a key factor during 
the development of arthritis. 
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